Literature DB >> 11719436

Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization.

Y Kotera1, K Shimizu, J J Mulé.   

Abstract

There is considerable controversy as to whether necrotic (lysate) or apoptotic tumor cells serve as the superior source of multiple tumor-associated antigens (TAAs) to pulse dendritic cells (DCs) for immunotherapeutic applications. Here, we show that standard procedures to induce apoptosis by UVB irradiation unequivocally result in a mixed population of viable, apoptotic, and necrotic tumor cells, necessitating additional purification. We used highly enriched apoptotic versus lysate of B16 melanoma cells to examine whether or not there are important distinctions between these two sources of TAAs for loading of DCs. Our results demonstrate that although some differences exist between the two forms of TAAs in expression of heat shock proteins, as well as production of interleukin-12 by pulsed DCs, their respective capacities to mature DCs phenotypically, as well as to elicit both effective immune priming and antitumor therapeutic efficacy in vivo when presented by DCs, are equivalent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719436

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model.

Authors:  Brittany L Bunch; Krithika N Kodumudi; Ellen Scott; Jennifer Morse; Amy Mackay Weber; Anders E Berglund; Shari Pilon-Thomas; Joseph Markowitz
Journal:  Cancer Immunol Immunother       Date:  2020-06-18       Impact factor: 6.968

Review 2.  Natural endogenous adjuvants.

Authors:  Kenneth L Rock; Arron Hearn; Chun-Jen Chen; Yan Shi
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

3.  Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.

Authors:  Reza Mahdian; Parviz Kokhaei; Hossein Motieian Najar; Katja Derkow; Aniruddha Choudhury; Håkan Mellstedt
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Authors:  David W O'Neill; Nina Bhardwaj
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

5.  Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.

Authors:  Paul Hatfield; Alison E Merrick; Emma West; Dearbhaile O'Donnell; Peter Selby; Richard Vile; Alan A Melcher
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

6.  Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

Authors:  Ozcan Met; Jens Eriksen; Inge Marie Svane
Journal:  Mol Biotechnol       Date:  2008-06-10       Impact factor: 2.695

7.  Intratumoral injection of interferon-gamma gene-modified dendritic cells elicits potent antitumor effects: effective induction of tumor-specific CD8+ CTL response.

Authors:  Jianping Pan; Minghui Zhang; Jianli Wang; Qingqing Wang; Dajing Xia; Wenji Sun; Lihuang Zhang; Hai Yu; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2005-02-12       Impact factor: 4.553

8.  Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Authors:  Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

9.  Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Authors:  Norimasa Matsushita; Hiroshi Komine; Annabelle Grolleau-Julius; Shari Pilon-Thomas; James J Mulé
Journal:  Cancer Immunol Immunother       Date:  2010-01-08       Impact factor: 6.968

Review 10.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.